1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Suvanza Pharma, LLC

Suvanza Pharma, LLC

SUVZ
Suvanza Pharma, LLCUS flagOther OTC
0.00
USD
- -
- -
1.01MMarket Cap
1993 Y
1994 Y
1995 Y
1996 Y
1997 Y
1998 Y
1999 Y
2000 Y
2001 Y
2002 Y
TTM
Revenue per Share
382.66
630.53
512.71
643.93
2.34
- -
15.62
0.02
0.61
- -
0.07
Basic EPS, GAAP
42
51
37
47.2
75
-206.76
-314.43
-151.95
-251.08
-165.21
-146.89
Free Cash Flow per Basic Share
28
32.45
-18.5
-36.14
-168.75
-122.81
-139.7
-243.36
-166.17
-130
-111.58
Dividend per Share
32.67
23.18
15.86
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
46.67
83.45
37
332.15
452.01
264.47
246.72
206.39
27.1
-51.6
-75.58
Tangible Book Value per Share
60.67
125.18
351.5
332.15
452.34
263.77
316.79
283.9
119.5
67.35
39.96
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
8
14
19
31
- -
- -
1
- -
- -
- -
- -
Operating Margin (%)
15.85
13.24
8.76
10.26
-1,400
- -
-703.68
-1,036,300
-42,888.24
- -
-223,171.43
Depreciation Expense
- -
- -
- -
1
- -
1
1
- -
4
4
4
Net Income, GAAP
1
1
1
2
3
-9
-16
-9
-21
-17
-15
Effective Tax Rate (%)
35.71
35.29
33.33
37.75
33.56
- -
- -
- -
- -
- -
- -
Profit Margin (%)
10.98
8.09
7.22
7.33
3,200
- -
-2,012.83
-946,800
-40,905.88
- -
-220,142.86
Working Capital
1
2
12
15
17
11
16
7
5
2
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
1
3
13
16
19
12
16
18
10
7
4
Return on Invested Capital (%)
- -
58.24
14.17
13.48
-5.12
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
78.57
87.5
26.12
18.19
-58.67
-131.93
-74.88
-276.1
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'02
Dec'02
Mar'03
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'02
Dec'02
Mar'03
Total Current Assets
5
3
2
Cash, Cash Equivalents & STI
5
2
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
2
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-13.18%
-30.88%
Free Cash Flow
- -
21.6%
-4.06%
Net Income, GAAP
- -
-49.45%
-19.3%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2001
- -
- -
- -
- -
- -
2002
- -
- -
- -
- -
- -
2003
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2001
-51.14
-60.78
-64.73
- -
-251.08
2002
-44.16
-55.82
-34.06
- -
-165.21
2003
-24.44
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2001
- -
- -
- -
- -
- -
2002
- -
- -
- -
- -
- -
2003
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Nardo Zaias
Sector
Healthcare
Industry
Biotechnology
Address
5401 Collins Avenue Miami Beach FL United States of America 33140
IPO Date
Feb 24, 1995
Website
suvanza.com
Similar Companies
EQRx, Inc. (EQRXW)
Universal Ibogaine Inc. (IBOGF)
TaiwanJ Pharmaceuticals Co., Ltd. (6549.TWO)
Telix Pharmaceuticals Limited (TLX.AX)
InMed Pharmaceuticals Inc. (INM)
Ascentage Pharma Group International (AAPG)
Business
Suvanza Pharma, LLC (SUVZ) operates as an early-stage biotechnology company focused on developing advanced transdermal drug delivery systems for dermatological diseases; its primary product is RapiDerm, a proprietary skin drug delivery platform designed to enhance drug penetration for treating conditions including eczema, psoriasis, and other inflammatory skin disorders. The company offers research, development, and commercialization activities encompassing formulation development, preclinical studies, clinical trials, and regulatory efforts aimed at improving therapeutic outcomes and patient quality of life through innovative dermatology treatments. Founded in 2004 and headquartered in McClellan, California, with references to operations in Miami Beach, Florida, Suvanza targets pharmaceutical companies, dermatologists, and patients in the global dermatology market, seeking partnerships for product advancement and commercialization. Suvanza Pharma, LLC, formerly known as Hamilton PNG until its name change in March 2010 and previously associated with CenterSpan Communications Corporation, continues to prioritize R&D for its RapiDerm platform without reported recent acquisitions, funding rounds, or major strategic expansions in 2024 or 2025; the company maintains its focus on early-stage biotechnology operations in the dermatologic therapeutics segment.